サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536205

鎌状赤血球貧血治療薬の世界市場

Sickle-Cell Anemia Therapeutics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 181 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
鎌状赤血球貧血治療薬の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

鎌状赤血球貧血治療薬の世界市場は2030年までに49億米ドルに達する

2023年に21億米ドルと推定される鎌状赤血球貧血治療薬の世界市場は、2023～2030年の分析期間においてCAGR 12.5%で成長し、2030年には49億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるヒドロキシ尿素薬は、CAGR 12.0%を記録し、分析期間終了時には24億米ドルに達すると予測されます。オクスブライタ医薬品セグメントの成長率は、分析期間中CAGR 12.4%と推定されます。

米国市場は5億8,150万米ドルと推定、中国はCAGR 20.8％で成長すると予測

米国の鎌状赤血球貧血治療薬市場は2023年に5億8,150万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは20.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.6%と10.5%と予測されています。欧州では、ドイツがCAGR約7.7%で成長すると予測されています。

世界の鎌状赤血球貧血治療薬市場- 主要動向と促進要因まとめ

鎌状赤血球貧血は、ヘモグロビンSとして知られる異常ヘモグロビンの存在を特徴とする遺伝性血液疾患であり、赤血球を鎌状に歪ませる。この変形した細胞は血流を阻害し、疼痛、感染症、急性胸部症候群、脳卒中、その他の重篤な合併症を引き起こします。標準的な治療法は、疼痛緩和薬、抗生物質、輸血などの選択肢により、症状の管理と合併症の予防に重点を置いてきました。ヒドロキシ尿素は胎児ヘモグロビンの産生を誘導する薬剤で、疼痛性クリーゼや急性胸部症候群の頻度を減少させ、疾患修飾療法の主役となってきました。骨髄移植は治療法の可能性を提供するが、ドナーの入手可能性や手術に伴うリスクによって制限されています。

鎌状赤血球貧血治療薬における最近の進歩は有望であり、より効果的で根治的な治療への希望をもたらしています。遺伝子治療が画期的なアプローチとして登場し、いくつかの臨床試験で病気の原因となる遺伝子の欠損を修正する可能性が示されています。CRISPR-Cas9遺伝子編集やレンチウイルスベクターによる遺伝子付加などの技術は、こうした技術革新の最前線にあります。さらに、鎌状赤血球症の根本的な病態生理を標的とした新しい薬物療法も開発されています。これには、ヘモグロビンの酸素に対する親和性を高めるボクセロトールや、鎌状細胞の血管壁への接着を阻害するモノクローナル抗体であるクリザンリズマブが含まれ、血管閉塞性エピソードを軽減します。鎌状赤血球治療薬のパイプラインは強固で、様々な開発段階にある多数の治験薬があります。

鎌状赤血球貧血治療薬市場の成長は、いくつかの要因によって牽引されています。遺伝子治療とゲノム編集の技術的進歩により、治療の可能性が拡大し、有効性が向上しています。特にサハラ以南のアフリカ、インド、中東、米国の一部など、鎌状赤血球貧血の罹患率が高い地域での罹患率の増加が、効果的な治療に対する需要を促進しています。診断能力の向上は早期発見と介入を容易にし、これはこの疾患の管理と患者の予後の改善に極めて重要です。製薬会社による研究開発への多額の投資は、新規治療法の発見と商業化を加速させています。希少疾病用医薬品の指定や迅速承認などの規制上の支援により、新規治療への迅速なアクセスが促進されています。さらに、プレシジョン・メディシンの普及により、個人の遺伝子プロファイルに合わせた個別化治療の需要が高まっています。また、患者支援団体や公衆衛生の取り組みも、意識を高め、早期診断を促進し、革新的な治療の採用を支援する上で重要な役割を果たしており、鎌状赤血球貧血治療薬市場全体の成長に寄与しています。

調査対象企業の例（全86件）

  • Agios Pharmaceuticals, Inc.
  • Beam Therapeutics
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Chiesi Global Rare Disease
  • CRISPR Therapeutics
  • CSL Ltd.
  • Editas Medicine, Inc.
  • Emmaus Life Sciences, Inc.
  • GSK Plc
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Vertex Pharmaceuticals Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26843

Global Sickle-Cell Anemia Therapeutics Market to Reach US$4.9 Billion by 2030

The global market for Sickle-Cell Anemia Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 12.5% over the analysis period 2023-2030. Hydroxyurea Drug, one of the segments analyzed in the report, is expected to record a 12.0% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Oxbryta Drug segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$581.5 Million While China is Forecast to Grow at 20.8% CAGR

The Sickle-Cell Anemia Therapeutics market in the U.S. is estimated at US$581.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 20.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.6% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Sickle-Cell Anemia Therapeutics Market - Key Trends and Drivers Summarized

Sickle-cell anemia is a genetic blood disorder characterized by the presence of abnormal hemoglobin, known as hemoglobin S, which distorts red blood cells into a sickle shape. These misshapen cells can block blood flow, leading to pain, infections, acute chest syndrome, stroke, and other severe complications. The standard treatment has long been focused on managing symptoms and preventing complications, with options like pain relief medications, antibiotics, and blood transfusions. Hydroxyurea, a drug that induces the production of fetal hemoglobin, has been the mainstay of disease-modifying therapy, reducing the frequency of painful crises and acute chest syndrome. Bone marrow transplants offer a potential cure but are limited by donor availability and the risks associated with the procedure.

Recent advancements in sickle-cell anemia therapeutics are promising, bringing hope for more effective and curative treatments. Gene therapy has emerged as a groundbreaking approach, with several clinical trials demonstrating the potential to correct the genetic defect responsible for the disease. Techniques such as CRISPR-Cas9 gene editing and lentiviral vector-mediated gene addition are at the forefront of these innovations. Additionally, new drug therapies are being developed to target the underlying pathophysiology of sickle-cell disease. These include voxelotor, which increases hemoglobin's affinity for oxygen, and crizanlizumab, a monoclonal antibody that prevents the adhesion of sickle cells to blood vessel walls, thereby reducing vaso-occlusive episodes. The pipeline for sickle-cell therapeutics is robust, with numerous investigational drugs in various stages of development.

The growth in the sickle-cell anemia therapeutics market is driven by several factors. Technological advancements in gene therapy and genome editing are expanding treatment possibilities and improving efficacy. The increasing prevalence of sickle-cell anemia, particularly in regions with high rates of the disease, such as sub-Saharan Africa, India, the Middle East, and certain parts of the United States, is driving demand for effective treatments. Enhanced diagnostic capabilities are facilitating early detection and intervention, which is crucial for managing the disease and improving patient outcomes. Significant investments in research and development by pharmaceutical companies are accelerating the discovery and commercialization of novel therapies. Regulatory support, including orphan drug designations and fast-track approvals, is facilitating quicker access to new treatments. Additionally, the growing adoption of precision medicine is generating demand for personalized therapies tailored to individual genetic profiles. Patient advocacy groups and public health initiatives are also playing a vital role in raising awareness, promoting early diagnosis, and supporting the adoption of innovative treatments, thereby contributing to the overall growth of the sickle-cell anemia therapeutics market.

Select Competitors (Total 86 Featured) -

  • Agios Pharmaceuticals, Inc.
  • Beam Therapeutics
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Chiesi Global Rare Disease
  • CRISPR Therapeutics
  • CSL Ltd.
  • Editas Medicine, Inc.
  • Emmaus Life Sciences, Inc.
  • GSK Plc
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Vertex Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Sickle-Cell Anemia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Sickle-Cell Anemia Spurs Growth in Therapeutics Market
    • Advances in Gene Therapy Propel Growth
    • CRISPR Technology Expands Addressable Market Opportunity
    • Improved Diagnostic Techniques Generate New Opportunities
    • Here's How Personalized Medicine is Transforming the Market
    • Increasing Awareness Throws the Spotlight on Early Diagnosis and Treatment
    • Expanding Global Healthcare Infrastructure Drives Adoption in Emerging Markets
    • Biotechnology Innovations Propel Growth in Curative Therapies
    • Increasing Use of Artificial Intelligence in Drug Discovery Spurs Innovation
    • Technological Advancements in Blood Transfusion Techniques Generate Demand
    • Economic Burden of Sickle-Cell Disease Strengthens Business Case for Effective Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sickle-Cell Anemia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hydroxyurea Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hydroxyurea Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hydroxyurea Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oxbryta Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oxbryta Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Oxbryta Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adakveo Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adakveo Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Adakveo Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION